DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 50-278/S-037

SUPPLEMENT APPROVAL

Heritage Pharmaceuticals, Inc.
Attention: Laya Steve
Director, Regulatory Affairs
12 Christopher Way, Suite 300
Eatontown, NJ 07724

Dear Ms. Steve:

Please refer to your Supplemental New Drug Application (sNDA) dated March 27, 2014, received March 27, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tetracycline Hydrochloride Capsules, USP 250 mg and 500 mg.

We acknowledge receipt of your amendments dated September 3, and October 2, 2014; and February 27, March 18, and April 1, 2015.

This "Prior Approval" supplemental new drug application proposes changes to the **WARNINGS** and **PRECAUTIONS** sections of the labeling in response to an Agency Prior Approval Supplement Request Letter issued March 5, 2014. The **Microbiology** section was also updated.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions in Tables 1and 2 agreed to by you via email on April 23, 2015. These revisions are included in the enclosed labeling.

Table 1: Susceptibility Test Interpretive Criteria for Tetracycline									
Bacteria[a]	**Minimal Inhibitory Concentration (mcg/mL)**			**Zone Diameter (mm)**			**Agar Dilution (mcg/mL)**		
	S	**I**	**R**	**S**	**I**	**R**	**S**	**I**	**R**
Acinetobacter spp.	<4	8	>16	>15	12-14	<11	-	-	-
Anaerobes	-	-	-	-	-	-	<4	8	>16
Bacillus anthracis[a]	<1	-	-	-	-	-	-	-	-
Brucella species[a]	<1	-	-	-	-	-	-	-	-
Enterobacteriaceae	<4	8	>16	>15	12-14	<11	-	-	-
Franciscella tularensis[a]	<4	-	-	-	-	-	-	-	-
Haemophilus influenzae	<2	4	>8	>29	26-28	<25	-	-	-
Mycoplasma pneumoniae	-	-	-	-	-	-	≤2		
Neisseria gonorrhoeae[b]	-	-	-	>38	31-37	<30	<0.25	0.5-1	>2
Staphylococcus aureus	<4	8	>16	>19	15-18	<14	-	-	-
Streptococcus pneumoniae	<1	2	>4	>28	25-27	<24	-	-	-
Streptococcus pyogenes	<2	4	>8	>23	19-22	<18	-	-	-
Vibrio cholerae	<4	8	>16	>15	12-14	<11	-	-	-
Yersinia pestis	<4	8	>16	-	-	-	-	-	-

[a]The current absence of resistance isolates precludes defining any results other than "Susceptible". If isolates yielding MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.

[b]Gonococci with 30 mcg tetracycline disk zone diameters of less than 19 mm usually indicate a plasmid-mediated tetracycline resistant *Neisseria gonorrhoeae* isolate. Resistance in these strains should be confirmed by a dilution test (MIC greater than or equal to 16 mcg/mL).

Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Tetracycline			
QC Strain	**Minimal Inhibitory Concentration (mcg/mL)**	**Zone Diameter (mm)**	**Agar Dilution (mcg/mL)**
Enterococcus faecalis ATCC 29212	8 - 32	-	-
Escherichia coli ATCC 25922	0.5 - 2	18 - 25	-
Haemophilus influenzae ATCC 49247	4 - 32	14 - 22	-
Mycoplasma pneumoniae ATCC 29342	0.06-0.5	-	0.06-0.5
Neisseria gonorrhoeae ATCC 49226	-	30 - 42	0.25 - 1
Staphylococcus aureus ATCC 25923	-	24 - 30	-
Staphylococcus aureus ATCC 29213	0.12 - 1	-	-
Streptococcus pneumoniae ATCC 49619	0.06 - 0.5	27 - 31	-
Bacteroides fragilis ATCC 25285	-	-	0.12 - 0.5
Bacteroides thetaiotaomicron ATCC 29741	-	-	8 - 32

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your October 2, 2014, submission containing final printed carton and container labels.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
04/27/2015